CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Feb 25

PMID 35203496

Authors

Motahareh Arjomandnejad

Acadia L Kopec

Allison M Keeler

Affiliations

Soon will be listed here.

Abstract

Regulatory T cells are critical for maintaining immune tolerance. Recent studies have confirmed their therapeutic suppressive potential to modulate immune responses in organ transplant and autoimmune diseases. However, the unknown and nonspecific antigen recognition of polyclonal Tregs has impaired their therapeutic potency in initial clinical findings. To address this limitation, antigen specificity can be conferred to Tregs by engineering the expression of transgenic T-cell receptor (TCR) or chimeric antigen receptor (CAR). In contrast to TCR Tregs, CAR Tregs are major histocompatibility complex (MHC) independent and less dependent on interleukin-2 (IL-2). Furthermore, CAR Tregs maintain Treg phenotype and function, home to the target tissue and show enhanced suppressive efficacy compared to polyclonal Tregs. Additional development of engineered CAR Tregs is needed to increase Tregs' suppressive function and stability, prevent CAR Treg exhaustion, and assess their safety profile. Further understanding of Tregs therapeutic potential will be necessary before moving to broader clinical applications. Here, we summarize recent studies utilizing CAR Tregs in modulating immune responses in autoimmune diseases, transplantation, and gene therapy and future clinical applications.

Citing Articles

Unlocking the Role of Treg Cells Immune Response and Infectious Risk Following CAR T-Cell Therapy in Patients with Cancer.

Dicharry D, Malek A Int J Mol Sci. 2025; 26(4).

PMID: 40004068 PMC: 11854923. DOI: 10.3390/ijms26041602.

The absolute number of circulating Treg cells is reduced in difficult-to-treat RA patients and is ameliorated by low-dose IL-2.

Yan H, Zi X, Yan H, Zhang X, Bai J, Gao C Front Immunol. 2025; 16:1522893.

PMID: 39981233 PMC: 11839615. DOI: 10.3389/fimmu.2025.1522893.

T-regulatory cells for the treatment of autoimmune diseases.

Fisher M, Sennikov S Front Immunol. 2025; 16:1511671.

PMID: 39967659 PMC: 11832489. DOI: 10.3389/fimmu.2025.1511671.

Cellular therapies in rheumatic and musculoskeletal diseases.

Franco-Fuquen P, Figueroa-Aguirre J, Martinez D, Moreno-Cortes E, Garcia-Robledo J, Vargas-Cely F J Transl Autoimmun. 2025; 10:100264.

PMID: 39931050 PMC: 11808717. DOI: 10.1016/j.jtauto.2024.100264.

Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases.

Huang Q, Zhu X, Zhang Y Biomark Res. 2025; 13(1):23.

PMID: 39901288 PMC: 11792665. DOI: 10.1186/s40364-025-00736-8.

References

Ferdosi S, Ewaisha R, Moghadam F, Krishna S, Park J, Ebrahimkhani M . Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat Commun. 2019; 10(1):1842. PMC: 6478683. DOI: 10.1038/s41467-019-09693-x. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Hector A, Schafer H, Poschel S, Fischer A, Fritzsching B, Ralhan A . Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection. Am J Respir Crit Care Med. 2015; 191(8):914-23. DOI: 10.1164/rccm.201407-1381OC. View

Mingozzi F, Maus M, Hui D, Sabatino D, Murphy S, Rasko J . CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007; 13(4):419-22. DOI: 10.1038/nm1549. View

Rubtsov Y, Rasmussen J, Chi E, Fontenot J, Castelli L, Ye X . Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28(4):546-58. DOI: 10.1016/j.immuni.2008.02.017. View

Miao C, Harmeling B, Ziegler S, Yen B, Torgerson T, Chen L . CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood. 2009; 114(19):4034-44. PMC: 2774545. DOI: 10.1182/blood-2009-06-228155. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Brunstein C, Miller J, Cao Q, McKenna D, Hippen K, Curtsinger J . Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2010; 117(3):1061-70. PMC: 3035067. DOI: 10.1182/blood-2010-07-293795. View

10.

Li Y, Frei A, Labrada I, Rong Y, Liang J, Samojlik M . Immunosuppressive PLGA TGF-β1 Microparticles Induce Polyclonal and Antigen-Specific Regulatory T Cells for Local Immunomodulation of Allogeneic Islet Transplants. Front Immunol. 2021; 12:653088. PMC: 8190479. DOI: 10.3389/fimmu.2021.653088. View

11.

Keeler A . Immune Responses to Adeno-Associated Virus-Mediated CRISPR Therapy. Hum Gene Ther. 2021; 32(23-24):1430-1432. DOI: 10.1089/hum.2021.29193.amk. View

12.

Lu Y, Chuang C, Chuang K, Chen I, Huang B, Lee W . Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biol. 2019; 17(6):e3000286. PMC: 6563948. DOI: 10.1371/journal.pbio.3000286. View

13.

Wright G, Notley C, Xue S, Bendle G, Holler A, Schumacher T . Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A. 2009; 106(45):19078-83. PMC: 2776462. DOI: 10.1073/pnas.0907396106. View

14.

Masteller E, Warner M, Tang Q, Tarbell K, McDevitt H, Bluestone J . Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol. 2005; 175(5):3053-9. DOI: 10.4049/jimmunol.175.5.3053. View

15.

Sojka D, Huang Y, Fowell D . Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology. 2008; 124(1):13-22. PMC: 2434375. DOI: 10.1111/j.1365-2567.2008.02813.x. View

16.

Wenzel S . Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012; 42(5):650-8. DOI: 10.1111/j.1365-2222.2011.03929.x. View

17.

Sun B, Zhang H, Franco L, Brown T, Bird A, Schneider A . Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther. 2005; 11(6):889-98. DOI: 10.1016/j.ymthe.2005.01.012. View

18.

Bilate A, Lafaille J . Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol. 2012; 30:733-58. DOI: 10.1146/annurev-immunol-020711-075043. View

19.

Mount J, Herzog R, Tillson D, Goodman S, Robinson N, McCleland M . Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002; 99(8):2670-6. DOI: 10.1182/blood.v99.8.2670. View

20.

Colella P, Ronzitti G, Mingozzi F . Emerging Issues in AAV-Mediated Gene Therapy. Mol Ther Methods Clin Dev. 2018; 8:87-104. PMC: 5758940. DOI: 10.1016/j.omtm.2017.11.007. View